国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Science and Health

US to ask panel whether to ban Abbott diet drug

(Agencies)
Updated: 2010-09-14 11:35
Large Medium Small

WASHINGTON – US health officials plan to ask expert advisers whether to pull Abbott Laboratories' controversial weight-loss drug Meridia off the market over heart risks.

The Food and Drug Administration, in documents released on Monday, said they wanted an advisory panel that meets Wednesday to consider options ranging from banning Meridia to leaving the prescription diet drug on the market without changes.

Related readings:
US to ask panel whether to ban Abbott diet drug 'Miracle diets' feed false promises to weight-watchers
US to ask panel whether to ban Abbott diet drug Experimental diet pill shows promise, little risk
US to ask panel whether to ban Abbott diet drug China faces big obesity challenge: researcher
US to ask panel whether to ban Abbott diet drug When dieting, watch your vitamins: study

US to ask panel whether to ban Abbott diet drugExpo encourages a low-carbon diet

Abbott intends to defend its drug at the meeting, saying the label already includes adequate warnings about the cardiovascular risks and volunteering additional measures to monitor use of the drug.

Meridia, part of a troubled group of weight-loss drugs, was never a blockbuster drug for Abbott and its sales have been falling. Some analysts see little impact, no matter what steps the FDA takes.

Meridia took in $340 million worldwide in 2008 and was expected to have slipped to $311 million in 2009, according to Thomson Reuters data, compared with Abbott's total net sales of $30.8 billion last year.

Analysts expect $101 million in global sales for Meridia this year. Shares of Abbott were off 0.4 percent to $51.32 in afternoon trading on the New York Stock Exchange.

While the FDA will make the final decision, it usually follows its advisers' recommendations.

The meeting underscores the checkered history of diet pills that so far have brought marginal weight loss to patients amid sharp safety concerns.

On Tuesday, the FDA releases staff assessments for another potential rival in the space, Arena Pharmaceuticals Inc's lorcaserin.

In July, an advisory panel failed to back Vivus Inc's Qnexa diet pill. Orexigen Therapeutics Inc also has a candidate before the FDA. All three companies are hoping to develop the first prescription diet drug that could offer better results with fewer risks.

Recent warning

Earlier this year, Abbott agreed to an FDA request for a new warning advising against Meridia's use in heart disease patients, and European sales were halted over safety concerns.

Meridia, which was approved in 1997, has drawn attention for years over potential cardiovascular risks, with consumer advocates calling for its withdrawal. Critics say the slight weight loss is not worth the risk.

Use of Meridia fell in late 2009, when early data from a company study called Scout showed some patients had more heart problems with Meridia than with a placebo.

In company documents, also released on Monday, Abbott said all available data for Meridia "continues to support its effectiveness as a weight loss agent in an appropriate patient population."

The FDA advisory panel will review the Scout trial, which studied the drug in patients with preexisting heart disease, diabetes or both. It found patients taking Meridia had more heart attacks and strokes than those given a placebo.

Those taking Meridia, known chemically as sibutramine, lost an average of 8.8 pounds (4 kilograms).

One FDA reviewer who looked at the study concluded that using Meridia for an average of 3.5 years increased the risk of major heart problems by 16 percent, and that no differences were seen among the various patients depending on which combination of preexisting conditions they had.

Risk vs benefit

Another staffer, an FDA epidemiologist, said in a separate memo released on Monday, "even a small increase in cardiovascular risk seems unwarranted" given the small number of pounds shed with Meridia and the potential to regain weight after stopping use.

Other safety information from various trials and medical literature was not strong enough to provide "convincing evidence" that Meridia's heart risk is low, this FDA staffer said.

Abbott, in its memo to the agency, said the Scout trial backs Meridia's current warning against use in patients with heart issues.

Critics say part of the problem is that the drug can still be used in a wider population and cause harm, and that many people have undiagnosed heart disease and could be at risk.

Consumer advocacy group Public Citizen petitioned the FDA in 2002 to pull the drug. More recently, the executive director of the New England Journal of Medicine raised doubts about keeping the drug on the US market.

Wedbush Securities analysts said that even if Meridia faces tougher restrictions or a ban, it is unlikely to shake Abbott, which "increasingly stands out as having one of the highest and most sustainable growth outlooks in the industry."

At most, Wednesday's meeting could stir negative headlines, but no material consequences, Wedbush analysts Phillip Nalbone and Jeffrey Chu said in a research note.

南阳市| 安丘市| 汝南县| 文登市| 滨州市| 二连浩特市| 南澳县| 五河县| 曲周县| 自治县| 玉环县| 沙田区| 兴山县| 宝坻区| 枝江市| 晋州市| 菏泽市| 太保市| 方城县| 托克逊县| 嘉禾县| 津南区| 丰城市| 玉门市| 射阳县| 北海市| 积石山| 五河县| 清远市| 庄浪县| 鄂尔多斯市| 汶川县| 固阳县| 将乐县| 喜德县| 肃北| 余姚市| 东安县| 易门县| 托里县| 石林|